Plasma Levels of Heat Shock Protein 90 Alpha Associated with Lung Cancer Development and Treatment Responses
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yinghong Zhang(Qingdao University), Lijian Zhang(University of Science and Technology of China), Xiaoqing Liu(Academy of Military Medical Sciences), Jiatao Lou(Shanghai Jiao Tong University), Mei Dong(307th Hospital of Chinese People’s Liberation Army), Qingtao Wang(Hubei University of Medicine), Baolan Li(Capital Medical University), Xiaohong Han(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 115
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
Revealing composition and structure dependent deep-level defect in antimony trisulfide photovoltaics
|Nature Communications|2021|229
Disturbed Gut-Liver axis indicating oral exposure to polystyrene microplastic potentially increases the risk of insulin resistance
|Environment International|2022|201